cGMP Violations Dietary Supplement Manufacturing: 40+ FDA Statistics

VelSafe Insights

cGMP Violations in Dietary Supplement Manufacturing: 40+ Statistics from FDA 483 Data Through 2025-26

From 2023 to 2024, FDA observations specific to dietary supplement manufacturing jumped 46% – from 1,083 to 1,578. In FY2024 the agency conducted 600 inspections, up from 500 the prior year. The top violation in both 2023 and 2024 was identical: failure to establish product specifications. The U.S. dietary supplement market reached $70 billion in 2025, with 13,000-15,000 registered facilities and an annual inspection rate of approximately 5%. This article compiles 40+ statistics on the most common cGMP violations, FDA inspection trends, and regulatory changes through 2025-26.

40+ Statistics

FDA 483 Data FY2023-2024

21 CFR Part 111 Violations

2025-26 Regulatory Updates

46%

Increase in dietary supplement 21 CFR Part 111 observations from 2023 (1,083) to 2024 (1,578)

cGMP Consulting / FDA data, 2025

~50%

of dietary supplement facilities inspected in FY2023 received a Form 483 observation citing cGMP violations

Policy Canary / FDA FY2023

Annual inspection rate – only about 5% of the 13,000-15,000 registered supplement facilities are inspected each year

FDA ODSP Director / SupplySide, 2025

The dietary supplement industry operates on a fundamental compliance paradox: the FDA inspects roughly 5% of registered facilities each year, yet when an inspection does occur, approximately half of all facilities receive a Form 483 citing cGMP violations. And the observations have not changed substantially year over year. The same deficiencies that dominated 483 reports a decade ago – failure to establish product specifications, inadequate component identity testing, weak documentation – continue to account for the majority of citations in 2023 and 2024.

The industry is also growing. The U.S. dietary supplement market reached $70 billion in 2025, with more than 70% of American adults taking at least one supplement. FDA inspections grew from approximately 500 in FY2023 to 600 in FY2024, including a more than doubling of foreign facility inspections. Observations specific to dietary supplements jumped 46% year over year. Below we have compiled 40+ statistics from FDA Form 483 data, FOIA-obtained inspection records, and regulatory sources covering the most common violations, enforcement trends, and 2025-26 regulatory changes that manufacturers need to understand.

Editor's Choice: Key cGMP Violation Statistics for Dietary Supplements

33%

of facilities receiving a Form 483 are cited for failure to establish finished product specifications – the single most common violation under 21 CFR 111.70(b)(1), and the top observation in both FY2023 and FY2024. (Natural Products Insider FOIA / FDA; Policy Canary, 2026)

20%

of 483-receiving facilities cited for failure to establish component specifications (21 CFR 111.70(b)(2)) – the second most common violation, requiring purity, strength, and composition specs for ingredients. (Natural Products Insider FOIA, FY2023)

18%

of 483-receiving facilities cited for failure to establish an identity specification for each component (21 CFR 111.70(b)(1)) – the third most common violation in FY2023 inspection data. (Natural Products Insider FOIA, FY2023)

1,578

FDA observations specific to dietary supplement manufacturing (21 CFR Part 111) in 2024, up from 1,083 in 2023 – a 46% year-over-year increase even as overall food industry 483s declined. (cGMP Consulting, March 2025)

600

dietary supplement facility inspections conducted by FDA in FY2024, up from approximately 500 in FY2023. Foreign inspections more than doubled from 40 to 90. (SupplySide Supplement Journal FOIA, January 2025)

$70B

U.S. dietary supplement market valuation in 2025, projected to reach $128 billion by 2033 – the commercial context in which 13,000-15,000 registered facilities operate under 21 CFR Part 111. (MarketSpark Solutions, 2026)

1. FDA Inspection Activity and Industry Scale: The Numbers Behind cGMP Enforcement

FDA Dietary Supplement Inspection Growth FY2023 to FY2024

FY2023

~500

Total inspections

461 domestic + 40 foreign

FY2024

600

Total inspections

510 domestic + 90 foreign (foreign 2.25x increase)

483 Observations

+46%

1,083 in 2023 to 1,578 in 2024

Even as overall food industry 483s declined

Sources: SupplySide Supplement Journal (FOIA, January 2025); cGMP Consulting (March 2025)

FDA conducted 600 dietary supplement facility inspections in FY2024, growing from approximately 500 in FY2023. Foreign inspections more than doubled, rising from 40 to 90 – a signal of increased scrutiny of international supply chains. (SupplySide Supplement Journal FOIA data, January 2025)
Despite growing inspection activity, 600 inspections represent approximately 5% of the 13,000-15,000 registered dietary supplement facilities – FDA inspects around 500-600 facilities per year against a much larger base. (FDA ODSP Director Cara Welch, Ph.D., cited in SupplySide, 2025)
Dietary supplement-specific 483 observations jumped 46% from 1,083 in 2023 to 1,578 in 2024, even as overall food industry 483 observations declined – meaning supplement enforcement intensified within a broader context of reduced food sector citations. (cGMP Consulting, March 2025)
Nearly half of all dietary supplement facilities inspected in FY2023 received a Form 483 observation – confirming that when FDA does arrive, the odds of finding a violation are high, even after cGMP regulations have been in force since 2007. (Policy Canary, March 2026; Natural Products Insider FOIA)
The U.S. dietary supplement market reached $70 billion in 2025, with more than 70% of American adults taking at least one supplement and the market projected to reach $128 billion by 2033 – the commercial scale against which these enforcement numbers must be understood. (MarketSpark Solutions, 2026)
The vitamin and supplement manufacturing sector was valued at $34.1 billion in 2025 (manufacturing revenue, distinct from retail market), growing at 2.0% annually. (IBISWorld, April 2025)

2. The Top cGMP Violations: What FDA 483 Data Shows for 2023-2024

33% of 483-receiving facilities

Finished product specifications not established (21 CFR 111.70(b)(1))

~20% of 483-receiving facilities

Component specifications not established (21 CFR 111.70(b)(2))

~18% of 483-receiving facilities

Identity specification not established per component (21 CFR 111.70(b)(1))

Frequent – Subpart E top category

Production and process control system failures (21 CFR 111 Subpart E)

Recurring across all years

Supplier qualification failure – inadequate supplier CoA verification

Sources: Natural Products Insider (FOIA, FY2023); Policy Canary (2026); Nutritional Outlook; Eurofins USA

Failure to establish finished product specifications (21 CFR 111.70(b)(1)) was the top FDA observation in both FY2023 and FY2024 – cited in approximately 33% of all facilities that received a Form 483. Manufacturers must specify identity, purity, strength, composition, and contaminant limits in writing. (Natural Products Insider FOIA, FY2023; Policy Canary, 2026)
Failure to establish component specifications (21 CFR 111.70(b)(2)) was the second most common citation at approximately 20% of 483-receiving facilities – requiring manufacturers to ensure specs for purity, strength, and composition of dietary ingredients are met. (Natural Products Insider FOIA, FY2023)
Failure to establish an identity specification for each component appeared in approximately 18% of 483-receiving facilities in FY2023 – the third most common violation, requiring at least one appropriate test to verify ingredient identity before use. (Natural Products Insider FOIA, FY2023)
The most frequently cited subpart since 2009 has been 21 CFR 111 Subpart E – Requirement to Establish a Production and Process Control System – spanning five sub-categories of process control failures that inspectors consistently find. (Eurofins USA enforcement trends analysis)
Supplier qualification failure is a persistent top-five observation – requiring manufacturers to establish reliability of supplier certificates of analysis through independent confirmation, not merely on-file acceptance. Relying on a supplier’s CoA alone without independent verification does not satisfy 21 CFR 111.75(a)(2)(ii)(A). (Nutritional Outlook; Certified Laboratories, 2025)
The top two observations in both 2023 and 2024 are specification failures, not sanitation or contamination – confirming that the most pervasive compliance gap is documentation and quality planning at the design stage, not execution on the production floor. (cGMP Consulting, March 2025)

3. Product and Component Specifications: Why 33% of Facilities Fail the Same Test

What FDA Requires

Written specifications for identity, purity, strength, and composition of every finished product, plus contaminant limits. Must exist before batch release decisions can be made objectively.

What Inspectors Find

Many firms have no written specifications, or specifications that are incomplete. Contract manufacturers face particular scrutiny – their failures cascade across every brand they manufacture for.

The Consequence

Without approved specifications, batch release decisions lack objective criteria. Products may be released that do not meet the label claims – exposing consumers to risk and manufacturers to recall liability.

The specification requirement is described by FDA as fundamental to building a quality product – yet it has been the top citation every year it has appeared prominently in inspection data, suggesting systemic non-compliance rather than isolated lapses. (Natural Products Insider, March 2025)
Without specifications, batch release decisions lack objective criteria – meaning a manufacturer cannot demonstrate, even to themselves, that a product meets its label claims before shipping it to consumers. (cGMP Consulting, March 2026)
Contract manufacturers face particular scrutiny in the specification area because their failures cascade across every brand they produce for – a single missing specification at a contract facility creates compliance exposure for multiple brand owners simultaneously. (Policy Canary, March 2026)
The identity testing requirement is specific: manufacturers must conduct at least one appropriate test or examination to verify the identity of each component before use. Relying on a supplier’s certificate of analysis alone – without independent verification – does not satisfy 21 CFR 111.75(a)(2)(ii)(A). (Policy Canary, 2026; Nutritional Outlook)
The recurring observation pattern reflects what inspectors describe as the regulatory equivalent of building a house without blueprints – companies conducting manufacturing activities without the foundational written controls that FDA’s regulations require to be in place before production begins. (Policy Canary, 2026)

4. Documentation and Record-Keeping Violations: Batch Records, SOPs, and Audit Trails

Missing batch record entries

Unsigned or incomplete MMRs

Outdated or vague SOPs

Missing supplier CoAs

No training documentation

Non-contemporaneous entries

Source: FDA 483 observation database; Policy Canary (2026); Certified Laboratories (2025); dicentra

Missing or incomplete batch records remain a top recurring observation – FDA requires every step of manufacturing to be documented with signatures, test results, and step completion records. Missing entries, even for steps that were performed correctly, constitute a cGMP violation. (Certified Laboratories, 2025; Policy Canary, 2026)
SOPs must be specific enough that a trained employee can follow them consistently. Inspectors find companies whose procedures are too vague to be actionable, inconsistent with actual practice, or simply absent for key manufacturing steps. (Policy Canary, 2026)
Master Manufacturing Records are a long-standing compliance gap. FDA reviews have found repeated failures to maintain MMRs – and within those records, failures to establish specifications for identity, purity, strength, composition, and contaminant limits. (dicentra cGMP training resource)
Non-contemporaneous record entries – filling in batch records after the fact rather than in real time – are a recurring documentation violation that inspectors specifically look for. In FDA’s view, if a process was not documented as it happened, it cannot be confirmed to have been performed correctly. (FDA; Certified Laboratories)
Supplier qualification records are a documented weak area: many companies lack adequate supplier testing records or supplier audit reports. A review of warning letter trends revealed minimal compliance for keeping adequate MMRs with supplier qualification documentation. (dicentra; Nutritional Outlook)

5. Sanitation, Contamination Control, and Quality Unit Violations

Equipment Sanitation

Visible residue, corrosion, inadequate cleaning schedules. Old material mixing with new batches causes contamination and incorrect dosage. Swab testing and visual verification are required documentation elements.

Air Handling and Airborne Contamination

Inadequate filtration or poor airflow in production areas cited repeatedly. Airborne contaminants can enter exposed product. Filter replacement schedules must be documented and followed.

Quality Unit Authority

A frequently cited observation: the Quality Unit is not given proper authority to perform its duties. FDA requires the Quality Unit to have the highest decision-making authority within the cGMP system.

Cross-Contamination

Allergens and raw herbs not handled in isolated environments. Especially dangerous when products contain common allergens (soy, milk, peanuts). Dedicated tools and physical separation required.

Poor sanitation is one of the most commonly observed physical facility violations – FDA reports machinery with visible residue or corrosion, floors with buildup, cobwebs in corners, and peeling surfaces in manufacturing areas. (FDA 483 observation data)
The Quality Unit observation is a persistent finding that surprises many manufacturers: FDA requires the Quality Unit to have the highest degree of authority within the company. When top management overrides QU decisions on batch release or specification changes, this constitutes a cGMP violation. (Nutritional Outlook; Policy Canary)
Cross-contamination between product lines – particularly when allergen-containing materials are not physically separated from other production – creates both cGMP violations and potential public health risks. FDA inspectors specifically review handling procedures for allergens as a standard inspection element. (FDA compliance program CP 7321.008, revised August 2025)
Improper handling of returned or damaged goods without retesting before reintroduction into production is a cited violation – returned goods may carry unknown contamination and must not re-enter production streams without documented evaluation. (FDA 483 observation data)
FDA’s compliance program for dietary supplements (CP 7321.008, revised August 2025) specifically directs inspectors to evaluate the potential for contamination, allergen cross-contact, and pests, as well as the adequacy of employee hygiene. (FDA CP 7321.008, August 2025)

6. 2025-26 Regulatory Changes Affecting Dietary Supplement cGMP Compliance

Early 2025

FDA established Human Foods Program (HFP) – consolidating regulatory oversight with new enforcement pathways

Health Genesis, 2025

Jan 2025

Red No. 3 (erythrosine) ordered removed from dietary supplement products – reformulation deadline January 15, 2027

FDA / Health Genesis, 2025

Feb 2025

FDA updated its Dietary Supplement Ingredient Directory with expanded information on select ingredients and substances

FDA, February 2025

FDA established the Human Foods Program (HFP) in early 2025, consolidating previously scattered regulatory functions under unified leadership – fundamentally altering how supplement manufacturers interact with the agency on inspections, NDI notifications, and enforcement. (Health Genesis, 2025)
FDA experienced significant staffing reductions in 2025, including approximately 3,500 staff cuts (18% of workforce) and around 170 workers from the Office of Inspections and Investigations. This may affect inspection scheduling and follow-up enforcement capacity. (Health Genesis, 2025; SupplySide, May 2025)
On January 15, 2025, FDA ordered that Red No. 3 (erythrosine) may no longer be used in dietary supplement products. Manufacturers using this colorant have until January 15, 2027 to reformulate – a compliance deadline that requires immediate action for affected product lines. (FDA; Health Genesis, 2025)
On February 21, 2025, FDA updated its Dietary Supplement Ingredient Directory, expanding information on select ingredients and substances – manufacturers should verify that their ingredient classifications and documentation reflect the current directory. (FDA, February 2025)
FDA’s compliance program CP 7321.008 was revised and reissued in August 2025, updating the framework for dietary supplement inspections including domestic and foreign inspections, sampling protocols, and import examination procedures under 21 CFR Part 111. (FDA CP 7321.008, August 2025)
Third-party certification has emerged as both a quality signal and a competitive differentiator. Programs from NSF International and USP (Verified Mark) involve facility-level GMP audits that go beyond FDA’s minimum requirements – and major retailers increasingly require GMP certification from supplement suppliers. (Policy Canary, 2026; cGMP Consulting)

7. Consequences of cGMP Violations: Warning Letters, Recalls, and Enforcement Actions

Form 483 Observation

Issued at close of inspection when investigator observes conditions that may violate FD&C Act. Requires written response. Non-response within 15 days may escalate to Warning Letter.

Warning Letter

Public record posted on FDA website. Companies have 15 days to respond. Non-response or inadequate response may trigger injunctions, mandatory recalls, or seizures. Damages brand credibility immediately.

Import Alert / Facility Shutdown

Serious or repeat violations can result in import alerts blocking foreign-sourced products or injunctions preventing facility operation. These are the most severe enforcement tools short of criminal prosecution.

A Form 483 does not constitute a final agency determination of violation, but failure to respond adequately within 15 days can lead FDA to exercise other enforcement authorities including injunctions, mandatory recalls, and seizures. (Council for Responsible Nutrition)
Warning letters are publicly posted on FDA’s website, creating immediate reputational consequences. The presence of a warning letter can affect retailer relationships, investor confidence, and consumer trust – especially in a market where brand credibility is a primary differentiator. (FDA; CRN)
Western Innovations, Inc. received a warning letter on November 13, 2024 from FDA’s Human Foods Program for adulterated dietary supplement violations including cGMP failures – one of several active enforcement actions in the 2024-2025 period. (Cohen Healthcare Law, May 2025)
On December 15, 2025, FDA sent a letter to industry reminding manufacturers of their legal responsibilities for food recalls and calling for increased adoption of recall best practices – specifically targeting foods for vulnerable populations including infants and young children. (FDA, December 2025)
The risk of enforcement is not distributed equally: the 5% annual inspection rate means manufacturers may go years without an inspection – but when FDA does inspect, the odds of finding a Form 483-worthy violation approach 50%, and prior inspections with violations increase the probability of follow-up enforcement. (Policy Canary, 2026)

Key Takeaways for Dietary Supplement Quality and Compliance Teams

Specifications are the starting point – not an assumption

The top violation in both 2023 and 2024 is failure to establish finished product specifications – cited in 33% of 483-receiving facilities. If a manufacturer cannot produce written specifications for identity, purity, strength, and composition, they cannot demonstrate cGMP compliance to FDA, regardless of how clean the facility is.

Observations are rising sharply – not falling

A 46% increase in dietary supplement 483 observations from 2023 to 2024, against a backdrop of declining overall food industry citations, signals that FDA is specifically intensifying supplement oversight. The 600 inspections in FY2024 represent a year-over-year increase – and the trend is upward.

CoA acceptance without verification is a violation

Supplier qualification failure is a recurring top-five observation. 21 CFR 111.75(a)(2)(ii)(A) requires confirmation of supplier CoA results through independent testing or examination. Accepting a CoA at face value – without verification – does not satisfy FDA requirements, even for well-established suppliers.

Foreign supply chains face heightened scrutiny in 2025

Foreign facility inspections more than doubled from 40 in FY2023 to 90 in FY2024. Brands relying on international contract manufacturers or ingredient suppliers should not assume that physical distance from FDA creates regulatory distance. The agency is actively expanding foreign inspection capacity.

The Quality Unit must have genuine authority

Management override of Quality Unit decisions on batch release or specification changes is a documented violation category. FDA requires the QU to hold the highest decision-making authority within the manufacturing compliance system – not to be advisory, but to be determinative.

Red No. 3 reformulation deadline is January 2027

Manufacturers using erythrosine (Red No. 3) in dietary supplement products must reformulate by January 15, 2027. Products not reformulated by that date will be in violation. Quality teams should audit current formulations now and initiate reformulation workflows for any affected SKUs.

Sources

Government and Regulatory Sources

Industry and Research Sources

cGMP Violations in Dietary Supplement Manufacturing: 40+ Statistics Through 2025-26